Dr. Hamilton on Using pCR to Classify Risk in HER2+ Breast Cancer
Dr. Hamilton Discusses Challenges With Approved Treatments for HER2-Positive Breast CancerПодробнее
Dr. Hamilton on Overcoming Resistance to HER2-Targeted Therapy in Breast CancerПодробнее
EA1181/CompassHER2 pCR Research Study for HER2-Positive Breast Cancer - Full VideoПодробнее
Dr. Sledge on Using PCR To Determine Therapy Benefit for Breast CancerПодробнее
Dr. Hamilton on the Complex Treatment Algorithm for HER2+ Breast CancerПодробнее
Dr. Erika P. Hamilton on The Shifting Treatment Paradigm in HER2-Positive Breast CancerПодробнее
Dr. Han on the Importance of pCR in Breast CancerПодробнее
Dr. Hamilton on Research Needed in HER2-Positive Breast CancerПодробнее
Dr. O’Regan on Prognostic Value of pCR in HER2+ Breast CancerПодробнее
Dr. Hamilton on Phase 1 Trial for HER2 Positive Breast Cancer - Sarah CannonПодробнее
Dr. Erika P. Hamilton on ONT-380 in HER2-Positive Breast Cancer Patients With Brain MetastasesПодробнее
Dr. Hamilton on the Evolution of Treatment in HER2+ Breast CancerПодробнее
New horizons in high-risk HR+ HER2- EBC: Risk stratification for early identificationПодробнее
HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studiesПодробнее
Dr. Hamilton on the Results of the nextMONARCH Trial in Patients With HR+/HER2- Breast CancerПодробнее
Dr. Hamilton on FDA Approval of Adjuvant Pertuzumab Regimen in HER2+ Early Breast CancerПодробнее
Dr. Hamilton on How Neratinib Targets HER2+ Breast CancerПодробнее
Dr. Hamilton on Emerging Therapies in HER2+ Breast CancerПодробнее
Dr. Hamilton on the HER2CLIMB Trial in Metastatic HER2+ Breast CancerПодробнее
